Table 3. Hazard ratios for death of patients who survived ≥6 months post-HSCT.

	Univariate analysis HR (95% CI)	P value* (univariate)	Multivariate analysis HR (95% CI)	P value* (multivariate)
cGVHD a
Moderate-severe cGVHD	1.00 (ref)		1.00 (ref)
Non-cGVHD	4.73 (3.08–7.25)	<0.0001	4.72 (3.07–7.24)	<0.0001
Mild cGVHD	2.26 (1.40–3.65)	0.001	2.21 (1.37–3.56)	0.001
Sex b
Male	1.00 (ref)		1.00 (ref)
Female	0.98 (0.81–1.18)	0.842	0.97 (0.81–1.18)	0.791
Age at follow-up, years b
18–39	1.00 (ref)		1.00 (ref)
40–59	1.17 (0.92–1.49)	0.206	1.21 (0.95–1.54)	0.132
60–75	1.42 (1.10–1.83)	0.008	1.47 (1.14–1.91)	0.004
Calendar year at the start of follow-up b
2006–2010	1.00 (ref)		1.00 (ref)
2011–2015	0.89 (0.73–1.09)	0.258	0.86 (0.71–1.06)	0.150
Donor b
Related	1.00 (ref)		1.00 (ref)
Unrelated	1.11 (0.91–1.35)	0.322	1.10 (0.90–1.36)	0.348
Source for HSCT b
Bone marrow/cord blood	1.00 (ref)		1.00 (ref)
Peripheral blood stem cells	0.78 (0.63–0.95)	0.01–6	0.77 (0.63–0.95)	0.016

ref indicates reference group.

^aReported hazard ratio estimates are from the index dates (≥6 months post-HSCT) and 6 months forward. Hazard ratios for later follow-up timepoints are presented in Fig 2B.

^bHazard ratios are calculated for the full follow-up period.

^*P value produced using a univariate and multivariate Cox-regression model, respectively.